Living Cell Technologies Limited (ASX:LCT)
Living Cell Technologies Limited (LCT) is an Australia-based biotechnology company. The Company is focused on discovering and developing treatments for conditions, such as Parkinson's disease, diabetes, obesity and migraine. The Company's product pipeline consists of LP-003 for anti-obesity, LC-002 for migraine treatment and NTCELL for Parkinson's disease. Its Long-acting Pramlintide, LP-003 is a peptide drug that reduces caloric intake targeting obesity and it is also used for the treatment of diabetes. LC-002, is a receptor blocker targeting calcitonin gene-related peptide (CGRP), a neuropeptide hormone found in the nervous system. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson's disease. NTCELL's choroid plexus cells are coated with LCT's IMMUPEL technology to protect them from attack by the immune system. It has completed Phase I/IIa clinical trial and phase IIb trials for mid- to late-stage Parkinson's disease.